Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calcitriol and Ketoconazole in CRPC Post-Abiraterone
NCT03261336Phase 2Terminated
- Start
- Jan 2017
- Primary completion
- Feb 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of calcitriol in castration-resistant prostate cancer (CRPC). Primary endpoint: PSA Response Rate at 2 years. Started Jan 2017; status: terminated.
02
Drugs
calcitriol
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT03261336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03261336.